Table 3 Multivariate analysis using the Cox proportional hazards model.

From: AZGP1 activation by lenvatinib suppresses intrahepatic cholangiocarcinoma epithelial-mesenchymal transition through the TGF-β1/Smad3 pathway

Variables

HR (95% CI)

P-value

OS

TNM Stage III, IV

3.49 (0.98–12.44)

0.054

Lymph node metastasis

0.87 (0.21–3.59)

0.843

CEA > 5, μg/L

1.42 (0.67–3.01)

0.355

AZGP1

0.45 (0.21–0.96)

0.038

Tumor differentiation

2.06 (1.06–4.01)

0.033

Diabetes

1.72 (0.76–3.84)

0.182

RFS

TNM Stage III, IV

2.64 (0.73–9.62)

0.14

Lymph node metastasis

0.73 (0.17–3.21)

0.676

CEA > 5, μg/L

1.18 (0.56–2.47)

0.669

AZGP1

0.46 (0.21–0.96)

0.04

Diabetes

1.28 (0.55–2.97)

0.561

CA19-9 > 37, U/mL

1.91 (0.94–3.87)

0.074

Tumor differentiation

1.58 (0.81–3.05)

0.177

  1. Bold values indicates statistically significant p values less than 0.05.
Back to article page